Interesting study demonstrates that gait speed correlates with survival but not treatment intensity recommendation in older adults with blood #cancer who presented for treatment. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… #GeriOnc #Geriatrics #PallOnc ACS Journal Cancer Cancer and Aging Research Group (CARG) #GeriOnc Clark DuMontier, MD, MPH Andrew Hantel

55% and 26% of US states' crisis standards of care guidelines deprioritized or excluded some patients with cancer during scarce resource allocation, respectively. States with NCI CCCs had higher odds of palliative care provisions & lower odds of exclusions ja.ma/37v8fNs

A new study in Blood Advances highlights the need to address racial and ethnic #clinicaltrial enrollment disparities. Researchers say findings underscore need to create targeted diversification strategies to ensure representation. Read more: loom.ly/Tj1CUWY

Article here: Racial and Ethnic Enrollment Disparities and Demographic Reporting Requirements in Acute Leukemia Clinical Trials ashpublications.org/bloodadvances/…

Grateful to have played a part in this guidance from ASCO , now live in Journal of Clinical Oncology . ascopubs.org/doi/10.1200/JC…

Excited to share our study on the environmental and downstream human health effects of tele-oncology and decentralized cancer care as an oral abstract ASCO 2024 and simultaneously published in JAMA Oncology : jamanetwork.com/journals/jamao… Dana-Farber Division of Population Sciences Dana-Farber

Our new article in JAMA Network Open describes cancer trial eligibility and dose-modifications for individuals with Duffy null (DN) phenotype. 77% of trials & 54% of regimens excluded or modified doses for neutrophil counts within the DN reference range. jamanetwork.com/journals/jaman…

There should be Duffy null specific values for: -Dose modifications on and off trial -CTCAE toxicities -Remission criteria -Clinical trial inclusion >50% of trials require dose reductions within the Duffy null reference range. Lauren Merz Andrew Hantel nejm.org/doi/full/10.10…

Hantel et al. write that cancer research and care practices that adversely affect people with the Duffy null phenotype are an underrecognized and widespread source of discrimination against people of African or Arab ancestry. Read the Perspective: nej.md/4iaZ3Bo

Andrew Hantel, MD, discusses a source of discrimination against some patients in cancer research and care practices. Full interview with NEJM Executive Managing Editor Stephen Morrissey (Stephen Morrissey): nej.md/495b2vY

Wendy Stock summarizes data presented in exciting session on AML, MDS & CLL prognosis & monitoring biomarkers #ASCO15